Variant position: 214 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 465 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DFEMDVVAMVNDTVATMISC YYEDHQCEVGMIVGTGCNACY
Mouse DFEMDVVAMVNDTVATMISC YYEDRQCEVGMIVGTGCNACY
Rat DFEMDVVAMVNDTVATMISC YYEDRQCEVGMIVGTGCNACY
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 465 Hexokinase-4
10 – 454 Hexokinase
204 – 443 Hexokinase large subdomain
228 – 228 ATP
231 – 231 Substrate
197 – 197 M -> V. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose.
211 – 211 I -> F. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose.
214 – 214 Y -> A. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose. No effect on affinity for ATP.
215 – 215 Y -> A. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose. Loss of inhibition by GCKR. No effect on affinity for ATP.
205 – 214
Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.
Cuesta-Munoz A.L.; Huopio H.; Otonkoski T.; Gomez-Zumaquero J.M.; Naentoe-Salonen K.; Rahier J.; Lopez-Enriquez S.; Garcia-Gimeno M.A.; Sanz P.; Soriguer F.C.; Laakso M.;
Cited for: VARIANT HHF3 CYS-214; CHARACTERIZATION OF VARIANT HHF3 CYS-214; FUNCTION; CATALYTIC ACTIVITY;
Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations.
Heredia V.V.; Carlson T.J.; Garcia E.; Sun S.;
J. Biol. Chem. 281:40201-40207(2006)
Cited for: CHARACTERIZATION OF VARIANTS HHF3 ILE-65; CYS-214; MET-455 AND VAL-456; MUTAGENESIS OF TYR-214 AND TYR-215; FUNCTION; CATALYTIC ACTIVITY;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.